[go: up one dir, main page]

FR2963005B1 - Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique - Google Patents

Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Info

Publication number
FR2963005B1
FR2963005B1 FR1056060A FR1056060A FR2963005B1 FR 2963005 B1 FR2963005 B1 FR 2963005B1 FR 1056060 A FR1056060 A FR 1056060A FR 1056060 A FR1056060 A FR 1056060A FR 2963005 B1 FR2963005 B1 FR 2963005B1
Authority
FR
France
Prior art keywords
pyridazines
oxadiazoles
derivatives
preparation
therapeutic application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1056060A
Other languages
English (en)
Other versions
FR2963005A1 (fr
Inventor
Eykmar Fett
Patrick Mougenot
Claudie Namane
Eric Nicolai
Christophe Philippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1056060A priority Critical patent/FR2963005B1/fr
Priority to ARP110102637A priority patent/AR088021A1/es
Priority to AU2011281173A priority patent/AU2011281173A1/en
Priority to JP2013520278A priority patent/JP2013532655A/ja
Priority to PCT/IB2011/053278 priority patent/WO2012011081A1/fr
Priority to EP11746655.7A priority patent/EP2595970B1/fr
Priority to RU2013107759/04A priority patent/RU2013107759A/ru
Priority to BR112013001534A priority patent/BR112013001534A2/pt
Priority to CA2806271A priority patent/CA2806271A1/fr
Priority to KR1020137001709A priority patent/KR20130041127A/ko
Priority to MX2013000907A priority patent/MX2013000907A/es
Priority to TW100126056A priority patent/TW201206442A/zh
Priority to UY0001033528A priority patent/UY33528A/es
Priority to CN2011800456589A priority patent/CN103201271A/zh
Priority to SG2013004320A priority patent/SG187564A1/en
Publication of FR2963005A1 publication Critical patent/FR2963005A1/fr
Application granted granted Critical
Publication of FR2963005B1 publication Critical patent/FR2963005B1/fr
Priority to US13/747,862 priority patent/US20130137691A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
FR1056060A 2010-07-23 2010-07-23 Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique Expired - Fee Related FR2963005B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR1056060A FR2963005B1 (fr) 2010-07-23 2010-07-23 Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
ARP110102637A AR088021A1 (es) 2010-07-23 2011-07-21 Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica
TW100126056A TW201206442A (en) 2010-07-23 2011-07-22 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics
PCT/IB2011/053278 WO2012011081A1 (fr) 2010-07-23 2011-07-22 Dérivés d'oxadiazole et de pyridazine, leur préparation et leur application en thérapie
EP11746655.7A EP2595970B1 (fr) 2010-07-23 2011-07-22 Dérivés d'oxadiazole et de pyridazine, leur préparation et leur application en thérapie
RU2013107759/04A RU2013107759A (ru) 2010-07-23 2011-07-22 Производные оксадиазола и пиридазина, их получение и применение в терапии
BR112013001534A BR112013001534A2 (pt) 2010-07-23 2011-07-22 derivados de oxadiazol e piridazina, suas preparações e suas aplicações em terapêutica
CA2806271A CA2806271A1 (fr) 2010-07-23 2011-07-22 Derives d'oxadiazole et de pyridazine, leur preparation et leur application en therapie
AU2011281173A AU2011281173A1 (en) 2010-07-23 2011-07-22 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics
MX2013000907A MX2013000907A (es) 2010-07-23 2011-07-22 Derivados y de piridazinas, su preparacion y su uso en terapeutica.
JP2013520278A JP2013532655A (ja) 2010-07-23 2011-07-22 オキサジアゾールおよびピリダジンの誘導体、これらの調製、ならびに、これらの治療用途
UY0001033528A UY33528A (es) 2010-07-23 2011-07-22 Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica
CN2011800456589A CN103201271A (zh) 2010-07-23 2011-07-22 噁二唑和哒嗪衍生物，它们的制备及它们的治疗应用
SG2013004320A SG187564A1 (en) 2010-07-23 2011-07-22 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics
KR1020137001709A KR20130041127A (ko) 2010-07-23 2011-07-22 옥사디아졸 및 피리다진의 유도체, 그의 제조법 및 그의 치료 용도
US13/747,862 US20130137691A1 (en) 2010-07-23 2013-01-23 Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056060A FR2963005B1 (fr) 2010-07-23 2010-07-23 Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
FR2963005A1 FR2963005A1 (fr) 2012-01-27
FR2963005B1 true FR2963005B1 (fr) 2012-08-17

Family

ID=43416427

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1056060A Expired - Fee Related FR2963005B1 (fr) 2010-07-23 2010-07-23 Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Country Status (16)

Country Link
US (1) US20130137691A1 (fr)
EP (1) EP2595970B1 (fr)
JP (1) JP2013532655A (fr)
KR (1) KR20130041127A (fr)
CN (1) CN103201271A (fr)
AR (1) AR088021A1 (fr)
AU (1) AU2011281173A1 (fr)
BR (1) BR112013001534A2 (fr)
CA (1) CA2806271A1 (fr)
FR (1) FR2963005B1 (fr)
MX (1) MX2013000907A (fr)
RU (1) RU2013107759A (fr)
SG (1) SG187564A1 (fr)
TW (1) TW201206442A (fr)
UY (1) UY33528A (fr)
WO (1) WO2012011081A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016323992B2 (en) 2015-09-16 2021-05-06 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
CN107651722A (zh) * 2016-07-24 2018-02-02 天津师范大学 基于3‑(5‑甲基‑1,3,4‑噁二唑)吡啶的三氟甲磺酸‑Ag(I)配合物在吸附染料中的应用
CN107662956A (zh) * 2016-07-28 2018-02-06 天津师范大学 3‑(5‑甲基‑1,3,4‑噁二唑)吡啶配体构筑的六氟磷酸‑Ag(I)配合物在吸附染料中的应用
WO2018170182A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
WO2020061113A1 (fr) 2018-09-18 2020-03-26 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
GB0427328D0 (en) * 2004-12-14 2005-01-19 Astrazeneca Ab Chemical compounds
NZ572586A (en) * 2006-05-30 2011-03-31 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
CA2651663A1 (fr) * 2006-05-30 2007-12-06 Astrazeneca Ab Composes chimiques
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
CN101827842A (zh) * 2007-08-17 2010-09-08 阿斯利康(瑞典)有限公司 作为dgat抑制剂的噁二唑衍生物
NZ587630A (en) * 2008-03-26 2011-07-29 Daiichi Sankyo Co Ltd Novel tetrahydroisoquinoline derivative
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2010132590A (ja) * 2008-12-03 2010-06-17 Astellas Pharma Inc オキサジアゾール化合物
CN102395572A (zh) * 2008-12-19 2012-03-28 阿斯利康(瑞典)有限公司 1,3,4-噁二唑衍生物及其治疗糖尿病的用途
FR2941457A1 (fr) * 2009-01-28 2010-07-30 Sanofi Aventis Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
WO2010086551A1 (fr) * 2009-01-28 2010-08-05 Sanofi-Aventis Dérivés de thiadiazoles et d'oxadiazoles, leur préparation et leur application en thérapeutique
EP2408766A1 (fr) * 2009-03-18 2012-01-25 Schering Corporation Composés bicycliques en tant qu'inhibiteurs de la diacylglycérol acyltransférase

Also Published As

Publication number Publication date
KR20130041127A (ko) 2013-04-24
UY33528A (es) 2012-02-29
AR088021A1 (es) 2014-05-07
CA2806271A1 (fr) 2012-01-26
US20130137691A1 (en) 2013-05-30
JP2013532655A (ja) 2013-08-19
EP2595970B1 (fr) 2015-01-07
BR112013001534A2 (pt) 2016-05-10
WO2012011081A1 (fr) 2012-01-26
CN103201271A (zh) 2013-07-10
MX2013000907A (es) 2013-03-05
AU2011281173A1 (en) 2013-02-07
FR2963005A1 (fr) 2012-01-27
RU2013107759A (ru) 2014-08-27
TW201206442A (en) 2012-02-16
SG187564A1 (en) 2013-03-28
EP2595970A1 (fr) 2013-05-29

Similar Documents

Publication Publication Date Title
FR2941696B1 (fr) Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2926555B1 (fr) Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2928922B1 (fr) Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2928921B1 (fr) Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2960875B1 (fr) Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2928149B1 (fr) Composes derives d'azetidines, leur preparation et leur application en therapeutique
EP2532652A4 (fr) Agent therapeutique de l'hepatite c
FR2945533B1 (fr) Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2958935B1 (fr) Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2963005B1 (fr) Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2948369B1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160331